Therefore, we analyzed the expression of IL-33/ST2 axis-related genes and clinical survival data of sarcoma from TCGA and GEO, hoping to provide clues as to whether IL-33 can modulate antitumor immunity and reverse the immunosuppressive tumor microenvironment in STS. The gene discussed is IL33; the disease is neoplasm.